Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-18-050356

Chief Financial Officer sold 45,000 shares at an average $19.34 ($870,200)

  • Chief Financial Officer acquired 45,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Option exercise +25,000 $2.62 $65,500 335,815 D: show line 1 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Option exercise +20,000 $4.75 $95,000 355,815 D: show line 2 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Sale −25,000 $18.00 $450,000 330,815 D: show line 3 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Sale −20,000 $21.01 $420,200 310,815 D: show line 4 in the form
Open-market sales · 45,000 sh · avg $19.34 · $870,200

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Option exercise · Stock Option (right to buy) −25,000 263,000 D: show line 5 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2018-09-06 Option exercise · Stock Option (right to buy) −20,000 243,000 D: show line 6 in the form
Loading xslF345X03/doc4.xml…